Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Prospect Venture Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
5,636,351Website Global Rank
1,670Website Monthly Traffic
Twitter Followers
Description
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2002 | Archemix | Series A | 51.8M |
| 1/2011 | SurePoint Medical | Venture Round | - |
| 8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
| 3/2008 | SurgRx | Series G | 19.8M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2005 | Nanosys | Series C | 0 |
| 4/2007 | Aspen MedTech | Venture Round | 1M |
| 6/2004 | Rejuvenon | Series B | 37M |
| 7/2010 | DFine | Venture Round | 36.2M |
| 8/2010 | Complete Genomics | Series E | 39M |
| 9/2004 | SurgRx | Series D | 11.9M |
| 6/2012 | SentreHEART | Series C | 26M |
| 4/2007 | SurgRx | Series F | 20M |
| 11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
| 9/2008 | Baxano | Series B | 20M |
| 7/2007 | Neomend | Series C | 6M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 10/2010 | NinePoint Medical | Series A | 33M |
| 1/2009 | Satori Pharmaceuticals | Series A | 22M |
| 3/2004 | Phylogix Inc. | Series B | 12M |
| 1/2010 | Neomend | Series D | 30M |
| 4/2004 | Archemix | Series B | 50M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Pathwork Diagnostics | Series C | 30M |
| 2/2002 | Nanosys | Series A | 15M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 6/2010 | Baxano | Series C | 30M |
| 10/2009 | Lux Biosciences | Series B | 50M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 8/2009 | Complete Genomics | Series D | 45M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 4/2003 | Nanosys | Series B | 0 |
| 7/2003 | Tercica | Series B | 44M |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 1/2011 | Satori Pharmaceuticals | Series B | 7M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
| 4/2008 | Transave | Series D | 35M |
| 7/2013 | NGM Biopharmaceuticals | Series C | 50M |
| 9/2016 | SentreHEART | Series D | 35M |
| 5/2006 | Cogentus Pharmaceuticals | Series A | - |
| 9/2006 | Alvine Pharmaceuticals | Series A | 8M |
| 12/2007 | Cogentus Pharmaceuticals | Series C | 62.5M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 5/2009 | Visiogen | Series D | 40M |
| 11/2005 | Hansen Medical | Venture Round | - |
| 4/2005 | Allux Medical | Series B | 5M |
| 2/2002 | Metreo | Series C | 15M |
| 4/2008 | DFine | Series D | 20M |
| 12/2005 | DFine | Series B | 6.5M |
| 12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 7/2005 | Vitae Pharmaceuticals | Series C | 15M |
| 4/2007 | Cogentus Pharmaceuticals | Series B | 15M |
| 10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
| 11/2007 | Vitae Pharmaceuticals | Series D | 15M |
| 3/2014 | Element Science | Series A | 12.5M |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 15M |
| 10/2011 | Azelon Pharmaceuticals | Series A | 4.5M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 1/2004 | Vitae Pharmaceuticals | Series B | 15M |
| 9/2004 | Allux Medical | Series A | 800k |
| 5/2005 | AVEO Oncology | Series C | 5M |
| 2/2007 | Visiogen | Venture Round | 24M |
| 10/2011 | Topica Pharmaceuticals | Series B | 27M |
| 3/2014 | NinePoint Medical | Series B | 34M |
| 8/2002 | Biospect | Series A | 4M |
| 1/2010 | DFine | Venture Round | 0 |
| 1/2009 | DFine | Venture Round | 0 |
| 6/2003 | Opus Medical | Series C | 13.6M |
| 6/2007 | Roxro Pharma | Series B | 42.7M |
| 10/2005 | Roxro Pharma | Series B | 21.6M |
| 3/2002 | Signature BioScience | Series E | 0 |
| 11/2011 | DFine | Venture Round | 25M |
| 9/2016 | SentreHEART | Series D | 0 |
| 3/2015 | NGM Biopharmaceuticals | Series D | 0 |
| 4/2014 | Nora Therapeutics | Series B | 0 |
| 3/2014 | Element Science | Series A | 0 |
| 3/2014 | NinePoint Medical | Series B | 0 |
| 7/2013 | NGM Biopharmaceuticals | Series C | 0 |
| 6/2012 | SentreHEART | Series C | 0 |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 0 |
| 11/2011 | NGM Biopharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
